Modulation of drug resistance by artificial transcription factors

Molecular Cancer Therapeutics

Volumn 7, Issue 3, 2008, Pages 688-697

  Blancafort, Pilar ^a,d   Tschan, Mario P ^a,b   Bergquist, Sharon ^a   Guthy, Daniel ^c   Brachat, Arndt ^c   Sheeter, Dennis A ^a   Torbett, Bruce E ^a   Erdmann, Dirk ^c   Barbas III, Carlos F ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF BERN   (Switzerland)

^c NOVARTIS PHARMA AG   (Switzerland)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE RIBOSYLATION FACTOR 1; ARTIFICIAL TRANSCRIPTION FACTOR; CISPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR 1; DENTIN MATRIX PROTEIN 1; DNA; ETOPOSIDE; FLUOROURACIL; PACLITAXEL; PROTEIN MDM2; PROTEIN P53; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; VINCRISTINE; ZINC FINGER PROTEIN;

ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER GENETICS; CANCER RESISTANCE; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DNA MICROARRAY; DRUG SENSITIVITY; DRUG TARGETING; ENZYME INHIBITION; FEMALE; GENE MUTATION; GENETIC ANALYSIS; GENETIC LINKAGE; GENOME ANALYSIS; HUMAN; HUMAN CELL; KAPOSI SARCOMA; PRIORITY JOURNAL; PROTEIN DOMAIN; TUMOR CELL; UPREGULATION;

BASE SEQUENCE; DNA PRIMERS; DRUG RESISTANCE, NEOPLASM; HELA CELLS; HUMANS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSCRIPTION FACTORS;

EID: 41649119943     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-07-0381     Document Type: Article

References (47)

1. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002;2:48-58.
2. Pommier Y, Sordet O, Antony S, Hayward RL, Kohn KW. Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks. Oncogene 2004;23:2934-49.
3. Makin G, Dive C. Apoptosis and cancer chemotherapy. Trends Cell Biol 2001;11:S22-5.
4. Kowalski P, Surowiak P, Lage H. Reversal of different drug-resistant phenotypes by an autocatalytic multitarget multiribozyme directed against the transcripts of the ABCtran sporters MDR1/P-gp, MRP2, and BCRP. Mol Ther 2005;11:508-22.
5. Kuznetsova M, Fokina A, Lukin M, Repkova M, Venyaminova A, Vlassov V. Catalytic DNA and RNA for targeting MDR1 mRNA. Nucleosides Nucleotides Nucleic Acids 2003;22:1521-3.
6. 125I-labelled oligonucleotides. Int J Radiat Biol 2004;80:889-93.
7. Nakamura K, Kubo A, Hnatowich DJ. Antisense targeting of Pglycoprotein expression in tissue culture. J Nucl Med 2005;46:509-13.
8. Izquierdo M. Short interfering RNAs as a tool for cancer gene therapy. Cancer Gene Ther 2005;12:217-27.
9. Xu D, McCarty D, Fernandes A, Fisher M, Samulski RJ, Juliano RL. Delivery of MDR1 small interfering RNA by self-complementary recombinant adeno-associated virus vector. Mol Ther 2005;11:523-30.
10. Xu D, Kang H, Fisher M, Juliano, RL. Strategies for inhibition of MDR1 gene expression. Mol Pharmacol 2004;66:268-75.
11. Sherr CJ. Principles of tumor suppression. Cell 2004;116:235-46.
12. Sagar S, Harris CC. p53: traffic cop at the crossroads of DNA repair and recombination. Nat Rev Mol Cell Biol 2005;6:44-55.
13. Hollstein M, Sidranki D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991;253:49-53.
14. 2-M arrest and apoptosis induced by paclitaxel in human sarcoma cells lacking both p53 and functional Rb protein. Mol Pharmacol 1999;55:1088-93.
15. WAF1/CIP1 and protects breast cancer cells from cisplatin-induced genotoxic damage. Int J Oncol 2005;26:649-59.
16. Yang W, Klos KS, Zhou X, et al. ErbB2 overexpression in human breast carcinoma is correlated with p21Cip1 up-regulation and tyrosine-15 hyperphosphorylation of p34Cdc2: poor responsiveness to chemotherapy with cyclophosphamide methotrexate, and 5-fluorouracil is associated with Erb2 overexpression and with p21Cip1 overexpression. Cancer 2003;98:1123-30.
17. Troester MA, Hoadley KA, Sorlie T, et al. Cell-type-specific responses to chemotherapeutics in breast cancer. Cancer Res 2004;64:4218-26.
18. Gartel AL, Tyner AL. Transcriptional regulation of the p21((WAF1/CIP1)) gene. Exp Cell Res 1999;246:280-9.
19. Gartel AL, Tyner AL. The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. Mol Cancer Ther 2002;1:639-49.
20. Blancafort P, Segal DJ, Barbas CF III. Designing transcription factor architectures for drug discovery. Mol Pharmacol 2004;66:1361-71.
21. Blancafort P, Magnenat L, Barbas CF III. Scanning the human genome with combinatorial transcription factor libraries. Nat Biotech 2003;21:269-74.
22. Lund CV, Blancafort P, Popkov M, Barbas CF III. Promoter targeted phage display selections with preassembled synthetic zinc finger libraries for endogenous gene regulation. J Mol Biol 2004;340:599-613.
23. Magnenat L, Blancafort P, Barbas CF III. In vivo selection of combinatorial libraries and designed affinity maturation of polydactyl zinc finger transcription factors for ICAM-1 provides new insights into gene regulation. J Mol Biol 2004;341:635-49.
24. Beerli RR, Segal DJ, Dreier B, Barbas CF III. Toward controlling gene expression at will: specific regulation of the erbB-2/HER-2 promoter by using polydactyl zinc finger proteins constructed from modular building blocks. Proc Natl Acad Sci U S A 1998;95:14628-33.
25. Chen C, Okayama H. High-efficiency transformation of mammalian cells by plasmid DNA. Mol Cell Biol 1987;7:2745-52.
26. Royer Y, Menu C, Liu X, Constantinescu SN. High-throughput gateway bicistronic retroviral vectors for stable expression in mammalian cells: exploring the biologic effects of STAT5 overexpression. DNA Cell Biol 2004;23:355-65.
27. Galimi F, Noll M, Kanazawa Y, et al. Gene therapy of Fanconi anemia: preclinical efficacy using lentiviral vectors. Blood 2002;100:2732-6.
28. Xu X, Leo C, Jang Y, et al. Dominant effector genetics in mammalian cells. Nat Genet 2001;27:23-9.
29. Lee DK, Kim YH, Kim JS, Seol W. Induction and characterization of Taxol-resistance phenotypes with a transiently expressed artificial transcriptional activator library. Nucleic Acids Res 2004;32:e116.
30. WAF1/CIP1 in AP-2α-mediated growth inhibition. J Biol Chem 2003;278:52093-101.
31. Ragione FD, Cucciolla V, Criniti V, Indaco S, Borriello A, Zappia V. p21Cip1 gene expression is modulated by Egr1: a novel regulatory mechanism involved in the resveratrol antiproliferative effect. J Biol Chem 2003;278:23360-8.
32. Fang M, Liu B, Schmidt M, Lu Y, Mendelsohn J, Fan Z. Involvement of p21Waf1 in mediating inhibition of paclitaxel-induced apoptosis by epidermal growth factor in MDA-MB-468 human breast cancer cells. Anticancer Res 2000;20:103-11.
33. DeFilippis RA, Goodwin EC, Wu L, DiMaio D. Endogenous human papillomavirus E6 and E7 proteins differentially regulate proliferation, senescence, and apoptosis in HeLa cervical carcinoma cells. J Virol 2003;77:1551-63.
34. Goodwin EC, DiMaio D. Repression of human papillomavirus oncogenes in HeLa cervical carcinoma cells causes the orderly reactivation of dormant tumor suppressor pathways. Proc Natl Acad Sci U S A 2000;97:12513-8.
35. Gartel AL, Feliciano C, Tyner AL. A new method for determining the status of p53 in tumor cell lines of different origin. Oncol Res 2003;13:405-8.
36. Friborg J, Jr., Kong W, Hottiger MO, Nabel GJ. p53 inhibition by the LANA protein of KSHV protects against cell death. Nature 1999;402:889-94.
37. Britschgi C, Rizzi M, Grob TJ, et al. Identification of the p53 responsive element in the promoter region of the tumor suppressor gene Hypermethylated in Cancer 1. Oncogene 2006;25:2030-9.
38. Mendez-Vidal C, Wilhelm MT, Hellborg F, Qian W, Wiman KG. The p53-induced mouse zinc finger protein wig-1 binds double-stranded RNA with high affinity. Nucleic Acids Res 2002;30:1991-6.
39. Hellborg F, Qian W, Mendez-Vidal C, et al. Human wig-1, a p53 target gene that encodes a growth inhibitory zinc finger protein. Oncogene 2001;20:5466-74.
40. Kuo M-L, Duncavage ER, Mathew R, et al. Arf induces p53-dependent and -independent antiproliferative genes. Cancer Res 2003;63:1046-53.
41. Inque K, Roussel M, Sherr C. Induction of Arf tumor suppressor gene expression and cell cycle arrest by transcription factor DMP1. Proc Natl Acad Sci U S A 2003;96:3393-998.
42. Tschan MP, Fischer KM, Fung VS, et al. Alternative splicing of the human cyclin D-binding Myb-like protein (hDMP1) yields a truncated protein isoform that alters macrophage differentiation patterns. J Biol Chem 2003;27:42750-60.
43. Dumontet C, Sikic B. Mechanisms of action and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death. J Clin Oncol 1999;17:1061-70.
44. Weaver BA, Cleveland DW. Decoding the links between mitosis, cancer and chemotherapy: the mitotic checkpoint, adaptation, and cell death. Cancer Cell 2005;8:7-12.
45. Yu D, Liu B, Yao J, Tan M, MacDonnell TJ, Hung MC. Overexpression of ErbB2 blocks Taxol-induced apoptosis by upregulation of p21Cip1, which inhibits p34Cdc2 kinase. Mol Cell 1998;2:581-91.
46. Fox BP, Kandpal RP. Invasiveness of breast carcinoma cells and transcript profile: Eph receptors and ephrin ligands as molecular markers of potential diagnostic and prognostic application. Biochem Biophys Res Commun 2004;318:882-92.
47. Dolnick R, Wu Q, Angelino NJ, et al. Enhancement of 5-fluorouracil sensitivity by an rTS signaling mimic in H630 colon cancer cells. Cancer Res 2005;65:5917-24.